The following guidelines are based on a systematic analysis of the literative which has been discussed by members of the ESOCAP committee and by external reviewers. The literature review and detailed methods of guideline development will be published in the European Respiratory Review, along with the list of external reviewers
Initial clinical assessment and decision on hospital referral
The management of a community-acquired lower respiratory tract infection (LRTI) should follow a systematic step-by-step process ( fig. 1 ), beginning with a detailed history and clinical examination. Attempts to identify the type of LRTI (pneumonia, acute bronchitis, superinfection of chronic bronchitis, or viral infection) are probably un-helpful outside hospital, since several studies have demonstrated that the sensitivity and specificity of clinical signs and symptoms are low for establishing such a classification. Therefore, the main goal of initial clinical evaluation is to determine whether the patient can be managed at home or whether there is evidence that suggests potential or immediate severity, or that the illness will follow a complicated course (table 1, fig. 2 ). All these features will guide the decision on hospital referral and admission ( fig. 2) .
Suggested questions for the management of a community-acquired LRTI Where to treat?
How to treat?
Should hospital referral be considered? ( 
Home management

Investigations
Most adults with LRTI in the community can be managed with no investigations. Investigations that are indicated in particular cases are shown in table 2.
Treatment
Therapeutic indications. In many adults with LRTI, the illness is self-limiting and its course will not be modified by antibiotic therapy. In addition, many LRTIs are due to viruses. Thus, such treatment should be considered only in patients with features suggesting the presence or risk factors of bacterial infection that is not self-limiting. These figure 3 .
Duration of antibiotic therapy. The recommended duration of antibiotic therapy is 5-7 days.
Hospital management
Investigations
In hospitalized patients, investigations are needed to ensure that treatment is adequate, and to look for additional criteria of severity ( fig. 4) .
Criteria for admission to the intensive care unit
Persistence or worsening of at least one of the conditions shown in table 3 justifies consideration of admission of the patient to an intensive care unit.
Treatment and assessment of response
The initial decision to give antibiotics and their choice depends on the clinical situation and on results of chest radiography and microbiological investigations (figs. 5 and 6). This decision and choice may be modified according to risk factors of particular micro-organisms (table 1) and have to be reconsidered after the results of microbiological examinations.
Pneumonia. Antibiotics are recommended in all patients with pneumonia. The most frequent pathogens are S. pneu-moniae , H. influenzae , anaerobes, L. pneumophila , Gramnegative enteric bacilli, S. aureus , C. pneumoniae and M. pneumoniae . In patients admitted to the intensive care unit S. pneumoniae and L. pneumophila are the leading causes of severe pneumonia. The clinical presentation cannot accurately predict the microbiological aetiology.
Recommended antibiotics are shown in figure 6 . The duration of treatment should be: 7-10 days in classical bacterial infection or uncomplicated community-acquired pneumonia (CAP); 10-14 days in suspected or proven M. pneumoniae or C. pneumoniae infection; and 21 days in suspected or proven L. pneumophila or S. aureus infection or severe CAP. The route of administration should be switched from i.v. to oral when fever has resolved and clinical condition is stable.
Assessment of response and investigations in nonresponding patients. The main criterion of response to antibiotic therapy is body temperature; fever should resolve within 2-3 days after initiation of antibiotic treatment. Progression of pulmonary infiltrates is also predictive of poor outcome in severe CAP.
In nonresponding patients, investigations, as shown in figure 7 , should be considered.
Exacerbation of chronic bronchitis. Indications for antibiotics. When the exacerbation is due to a bacterial infection, the most frequent pathogens are H. influenzae , S. pneumoniae and M. catarrhalis . Gram-negative bacilli, S. aureus , C. pneumoniae and M. pneumoniae are less frequently involved. Antibiotics are recommended in all patients with severe chronic obstructive pulmonary disease (COPD) exacerbations, and in nonsevere exacerbations when there is increased purulence of sputum and increased sputum volume and increased dyspnoea; valuable alternative regimens are described in figure 5.
Duration of antibiotic treatment. Antibiotics (except clarithromycin and azithromycin) should be administered for at least 7 days. Treatment should last 21 days when infection with L. pneumophila is suspected. 
Assessment of response and investigations in nonresponding patients. Symptoms of exacerbation should resolve
Antibiotics in community-acquired LRTIs managed in the hospital
Pneumonia
Exacerbation of chronic bronchitis Acute bronchitis Suspected influenza
Figure 6
Beta-lactam (e.g. amoxycillin 500-1,000 mg·8 h -1 orally) Or beta-lactam + betalactamase inhibitor* (e.g. amoxycillin + clavulanate 1 g·8 h -1 orally) Or new macrolide° (e.g. oral azithromycin 500 mg·24 h -1 for 3 days or 500 mg at day 1 then 250 mg·24 h -1 for 5 days, or oral clarithromycin 250-500 mg·12 h -1 for at least 5 days) Or second generation fluoroquinolone (e.g. ciprofloxacin 500 mg·12 h -1 or ofloxacin 400 mg·12 h -1 orally) Or Cefuroxime axetil* (750 mg·12 h -1 orally) Or pristinamycin (1g·8 h -1 orally) Or doxycyclin° (100mg·12 h -1 orally)
If severe condition or purulent sputum If onset of symptoms <48 h before assessment Consider amantadine (100 mg·12 h -1 for 5 days)
Treat during at least 7 days except when specified Assess response at day 5-7 (improvement of symptoms) Antibiotics in community-acquired pneumonia managed in the hospital
Medical ward
Intensive care unit Assess response at day 2-3 (fever, lack of progression of pulmonary infiltrates)
First choices Particular cases
Second generation cephalosporin (e.g. i.v. cefuroxime 750-1500 mg·8 h -1 ) or Third generation cephalosporin (e.g. i.v. cefotaxime 1 g·8 h -1 or i.v. ceftriaxone 1 g·24 h -1 ) or Betalactam-betalactamase inhibitor (e.g. oral or i.v. amoxycillin-clavulanate 1 g·8 h -1 ) or i.v. benzyl penicillin 1-4×10 6 units every 2-4 h or i.v. amoxicillin 1 g·6 h -1 or i.v. ampicillin 1 g·6 h -1 * +/-Macrolide (e.g. i.v. or oral erythromycin 1 g·8 h -1 , or oral azithromycin 500 mg·24 h -1 for 3 days or 500 mg at day 1 then 250 mg·24 h -1 for 5 days, or oral clarithromycin 250-500 mg·12 h -1 for at least 5 days) or Second generation quinolone (e.g. ofloxacine, ciprofloxacine) within 5-7 days after initiation of antibiotics. In nonresponding patients, bronchoscopy with protected specimen brush for Gram stain and quantitative culture should be considered.
Acute bronchitis or influenza. Hospitalized patients are those with an unstable underlying condition which puts them at risk of severity. Indications of antibiotics and amantadine are shown in figure 5. 
Prevention
